What Type of Drug Is Xeljanz? | 7 Powerful Facts

If you want to know what type of drug is Xeljanz, the short answer is that Xeljanz is an oral Janus kinase (JAK) inhibitor and a targeted immunosuppressant. Its active ingredient, tofacitinib, belongs to the disease-modifying antirheumatic drug class and reduces inflammation by interrupting immune-system signals involved in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and certain forms of juvenile idiopathic arthritis- accessdata.fda

Understanding Xeljanz’s drug type helps you understand why your doctor may prescribe it, how it differs from biologic medicines, why it requires laboratory monitoring, and why its safety warnings deserve careful attention. This article explains Xeljanz’s classification, mechanism, formulations, approved uses, safety profile, and major differences from other anti-inflammatory medicines.

1. Xeljanz Drug Classification

Xeljanz is a JAK inhibitor

Xeljanz belongs to a group of medicines called Janus kinase inhibitors, commonly shortened to JAK inhibitors. The active ingredient is tofacitinib, which selectively inhibits the activity of Janus kinase enzymes inside your cells.

The U.S. Food and Drug Administration classifies Xeljanz and Xeljanz XR as JAK inhibitors. The European Medicines Agency places tofacitinib within the pharmacotherapeutic group of immunosuppressants and specifically identifies it as a Janus-associated kinase inhibitor.

This classification describes how the medicine works rather than simply what disease it treats. Xeljanz does not belong to the same drug class as antibiotics, corticosteroids, painkillers, or traditional nonsteroidal anti-inflammatory drugs such as ibuprofen.

Instead, it targets intracellular signalling pathways that help immune cells communicate. By reducing selected immune signals, Xeljanz can decrease the inflammation responsible for joint pain, swelling, stiffness, intestinal inflammation, and other symptoms.

Xeljanz is an immunosuppressant

Xeljanz is also an immune-modulating drug or immunosuppressant. Your immune system normally protects you from infections and abnormal cells. In autoimmune and immune-mediated diseases, however, the immune system can become overactive and attack healthy tissues or produce excessive inflammation.

Tofacitinib reduces some immune-system activity. This action can help control disease-related inflammation, but it can also reduce your ability to fight certain infections. The FDA prescribing information warns that people taking Xeljanz may face an increased risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis.

The term immunosuppressant does not mean that Xeljanz completely shuts down your immune system. It affects particular signalling pathways, and the degree of immune suppression depends on factors such as your dose, health conditions, other medicines, age, and treatment duration.

Xeljanz is a conventional synthetic medicine

Xeljanz is a small-molecule medicine made through chemical synthesis. It is not a protein-based medicine and does not need to be injected or infused.

This makes Xeljanz different from many biologic disease-modifying antirheumatic drugs. Biologics generally consist of large, complex molecules produced using living cells. Examples include monoclonal antibodies and fusion proteins that target substances such as tumour necrosis factor or interleukins.

Xeljanz works inside cells rather than binding to one inflammatory substance outside the cell. Because it is a small molecule, you take it by mouth as a tablet, extended-release tablet, or oral solution, depending on your prescription and medical condition.

Xeljanz is a disease-modifying drug

For inflammatory arthritis, Xeljanz is classified as a disease-modifying antirheumatic drug, or DMARD. DMARDs do more than provide temporary pain relief. They aim to reduce the underlying inflammatory activity that drives symptoms and, in some conditions, contributes to tissue or joint damage.

This distinguishes Xeljanz from medicines that mainly relieve pain or reduce inflammation for a short period. A painkiller may make you feel more comfortable without changing the course of an autoimmune disease. A DMARD, by contrast, forms part of a long-term treatment plan intended to control disease activity.

Doctors may use Xeljanz alone or alongside selected non-biologic DMARDs, depending on your diagnosis and treatment history. The FDA label does not recommend combining Xeljanz with biologic DMARDs or potent immunosuppressants such as azathioprine or cyclosporine.

2. How Xeljanz Works

The role of Janus kinases

Your immune cells communicate through chemical messengers called cytokines. These messengers attach to receptors on the surface of cells and activate internal signalling pathways.

Janus kinases help transmit several of these signals from the cell surface to the cell nucleus. The main members of the JAK family include JAK1, JAK2, JAK3, and TYK2.

After a cytokine activates its receptor, JAK enzymes help activate proteins called signal transducers and activators of transcription, or STATs. STAT proteins then influence gene activity inside the cell. This process can encourage immune cells to grow, activate, migrate, and release additional inflammatory substances.

In simple terms, the JAK-STAT pathway acts like an internal communication system. Cytokines deliver the message, JAK enzymes help pass it along, and STAT proteins help the cell respond.

Tofacitinib interrupts immune signals

Tofacitinib inhibits JAK activity and reduces signalling from several cytokines involved in inflammation. The FDA describes tofacitinib as a JAK inhibitor that modulates signalling at the JAK stage, preventing the phosphorylation and activation of STAT proteins.

By interfering with this pathway, Xeljanz can reduce the activation of immune cells and the production of inflammatory responses. This helps explain why the medicine can work across several diseases that appear different on the surface but share immune-mediated inflammation.

For example, rheumatoid arthritis mainly affects the joints, while ulcerative colitis affects the lining of the colon and rectum. Both conditions involve abnormal immune activity and inflammatory signalling. Xeljanz acts on an internal pathway that participates in both processes.

Xeljanz does not work like a TNF blocker

A tumour necrosis factor inhibitor, often called a TNF blocker, targets TNF directly. TNF is one of the cytokines that contributes to inflammation in conditions such as rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease.

Xeljanz does not directly neutralise TNF. Instead, it blocks intracellular enzymes that help transmit signals from several cytokines, including some pathways associated with JAK1 and JAK3.

This difference affects how you take the medicine and how your clinician evaluates treatment. TNF blockers are commonly administered by injection or infusion, while Xeljanz is taken orally. In the United States, current prescribing information limits several approved uses of Xeljanz to patients who have had an inadequate response or intolerance to one or more TNF blockers.

Why the mechanism matters

The mechanism helps explain both the benefits and risks of Xeljanz. Blocking inflammatory signalling may reduce symptoms and disease activity, but the same pathway contributes to normal immune defence and blood-cell regulation.

As a result, your clinician may monitor your blood counts, liver enzymes, cholesterol levels, and signs of infection. The FDA label recommends evaluating tuberculosis and viral hepatitis, checking a complete blood count, reviewing liver function, and updating immunisations before treatment when appropriate.

Your doctor may also adjust or interrupt treatment if you develop certain blood-count abnormalities, a serious infection, or other clinically important problems.

3. Conditions Xeljanz Treats

Rheumatoid arthritis

Xeljanz is an approved treatment for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to, or cannot tolerate, one or more TNF blockers under the current U.S. label.

Rheumatoid arthritis is an autoimmune disease in which the immune system attacks the lining of the joints. Persistent inflammation can cause pain, swelling, stiffness, loss of function, and progressive joint damage.

As a DMARD, Xeljanz aims to reduce the disease process rather than simply mask pain. Your doctor may prescribe it alone or with methotrexate, depending on your treatment history and tolerance.

Psoriatic arthritis

Xeljanz is also used for active psoriatic arthritis, an inflammatory arthritis associated with psoriasis. The condition can affect your joints, tendons, fingers, toes, spine, and skin.

In the United States, the current label includes adults and certain children aged two years and older who have had an inadequate response or intolerance to one or more TNF blockers. The available formulation depends on your age, body weight, medical condition, and prescribing instructions.

Ankylosing spondylitis

Xeljanz is an oral JAK inhibitor used for adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers under the U.S. indication.

Ankylosing spondylitis mainly affects the spine and the joints connecting the spine to the pelvis. It can cause chronic back pain, stiffness, and reduced spinal movement.

Because the condition involves immune-mediated inflammation, blocking selected cytokine signalling pathways may help reduce disease activity in appropriate patients.

Ulcerative colitis

Xeljanz is approved for adults with moderately to severely active ulcerative colitis who have not responded adequately to, or cannot tolerate, one or more TNF blockers under the U.S. prescribing information.

Ulcerative colitis causes inflammation and ulcers in the lining of the colon and rectum. Symptoms may include bloody diarrhoea, urgency, abdominal pain, and frequent bowel movements.

Treatment for ulcerative colitis may involve an initial induction phase followed by maintenance therapy. Because higher doses can carry greater safety concerns, your gastroenterologist should use the lowest effective dose for the shortest appropriate duration when clinically possible.

Polyarticular-course juvenile idiopathic arthritis

Xeljanz tablets and oral solution are approved in the United States for children aged two years and older with active polyarticular-course juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

This form of juvenile idiopathic arthritis affects multiple joints and can interfere with movement, school activities, sleep, and normal childhood development.

Children do not necessarily receive the same dose or formulation as adults. The FDA label provides weight-based dosing for children, so you should never estimate a child’s dose from an adult prescription.

Juvenile psoriatic arthritis

The current U.S. label also includes active psoriatic arthritis in certain pediatric patients aged two years and older. Xeljanz may be prescribed as tablets or oral solution, depending on the child’s weight and ability to take the medicine.

Regulatory approvals differ between countries. The EMA describes use in children from two years of age with active polyarticular juvenile idiopathic arthritis or juvenile psoriatic arthritis, while treatment eligibility and prior-therapy requirements may vary by region.

For that reason, you should rely on the product information approved in your country and the instructions provided by your child’s specialist.

4. Xeljanz Forms and Dosing Concepts

Immediate-release Xeljanz

Immediate-release Xeljanz tablets contain tofacitinib and are usually taken more than once daily for several approved indications. The FDA label lists 5 mg and 10 mg tablet strengths.

You can take the immediate-release tablets with or without food, but you should take them consistently according to your prescription. Do not change the dose because your symptoms improve or worsen without speaking with your prescriber.

Xeljanz XR

Xeljanz XR is an extended-release formulation. It releases tofacitinib gradually and may allow once-daily administration for certain adult indications.

The FDA label lists 11 mg and 22 mg extended-release tablets. You must swallow the tablet whole. Do not crush, split, or chew it because doing so can interfere with the extended-release design.

Xeljanz XR is not automatically interchangeable with immediate-release Xeljanz. Your healthcare professional should supervise any switch between the two formulations.

You may notice an empty tablet shell in your stool after taking an extended-release tablet. This can occur because the medicine has been released while the shell passes through your digestive tract.

Xeljanz oral solution

Xeljanz oral solution contains 1 mg of tofacitinib per millilitre and may help children who cannot swallow tablets. You should measure the liquid with the supplied oral dosing syringe rather than a household teaspoon.

The child’s dose usually depends on body weight and may change as the child grows. Keep the bottle closed, store it as instructed, and follow the product’s directions about how long you can use the solution after opening.

Why you should not adjust your dose

The correct dose depends on your condition, treatment phase, kidney function, liver function, blood counts, age, body weight, and other medicines. Some medicines affect the enzymes that metabolise tofacitinib and may require dose adjustment.

Your doctor may also prescribe a lower dose if you have moderate kidney or liver impairment. Severe liver impairment may make Xeljanz unsuitable, and certain low blood-cell counts may require treatment interruption or discontinuation.

Taking more Xeljanz than prescribed does not necessarily improve your symptoms. It can increase your risk of infections and other serious adverse effects.

5. Safety Implications of Xeljanz’s Drug Type

Serious infections

Because Xeljanz suppresses selected immune signals, it can reduce your ability to fight infections. Serious infections reported with tofacitinib include pneumonia, cellulitis, urinary tract infections, diverticulitis, appendicitis, tuberculosis, invasive fungal infections, and shingles.

Contact your healthcare professional promptly if you develop symptoms such as:

• Fever, chills, or persistent sweating.
• Ongoing cough, shortness of breath, or coughing up blood.
• Painful urination or urinary frequency.
• Severe diarrhoea or abdominal pain.
• Painful skin redness, swelling, or a spreading rash.
• Unusual tiredness or unexplained weight loss.

Your clinician may pause treatment if you develop a serious infection until the infection is controlled. You should not start or continue Xeljanz without medical advice if you have an active serious infection.

Tuberculosis screening

Tuberculosis requires particular attention because treatment with an immunosuppressant can allow latent TB infection to become active.

Before starting Xeljanz, your healthcare professional may test you for latent or active TB. The FDA label recommends testing before and during therapy and treating latent TB before beginning treatment.

Tell your doctor if you have previously had TB, lived in or travelled to an area where TB is common, or spent time with someone who had active TB. In Kenya and other countries where TB remains an important public-health concern, you should give your clinician a complete exposure and medical history.

Cancer risk

The Xeljanz boxed warning includes malignancy, meaning cancer. Lymphomas and solid tumours have occurred in people treated with Xeljanz and other JAK inhibitors.

The FDA label reports a higher rate of malignancies, excluding non-melanoma skin cancer, in certain rheumatoid arthritis patients receiving Xeljanz compared with TNF blockers. It also notes higher observed rates of lymphoma and lung cancer in that study population.

Your individual risk may depend on factors such as age, smoking history, previous cancer, immune status, and other medicines. Tell your doctor if you currently smoke, previously smoked, have had cancer, or have received an organ transplant.

Heart attack, stroke, and blood clots

Xeljanz carries warnings about major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke. The FDA based its warning partly on a large randomized safety study involving rheumatoid arthritis patients aged 50 years or older who had at least one cardiovascular risk factor.

The label also warns about thrombosis, including deep-vein thrombosis, pulmonary embolism, and arterial thrombosis. Some events were serious or fatal.

Seek emergency medical care for possible heart attack or stroke symptoms, such as chest pressure, sudden weakness or numbness on one side of the body, difficulty speaking, severe dizziness, or sudden vision problems.

You should also seek urgent care for possible blood-clot symptoms, including sudden shortness of breath, chest pain that worsens when you breathe, or swelling, warmth, redness, or pain in an arm or leg.

Cholesterol and laboratory changes

Xeljanz may increase cholesterol levels. Your doctor may order a lipid panel after you begin treatment and periodically thereafter.

Tofacitinib can also affect lymphocytes, neutrophils, haemoglobin, and liver enzymes. These changes may not cause obvious symptoms, which is why blood tests form an important part of treatment monitoring.

Your clinician may delay treatment, reduce the dose, interrupt treatment, or stop treatment if laboratory results become unsafe. Never skip monitoring simply because you feel well.

Vaccinations

You should discuss your vaccination history with your doctor before starting Xeljanz. The FDA label recommends updating immunisations according to current guidelines and advises avoiding live vaccines during treatment.

Do not receive a vaccine while taking Xeljanz without first asking your healthcare professional. Your doctor may recommend completing certain vaccinations before treatment begins, depending on your health status and local immunisation guidance.

Pregnancy and breastfeeding

Tell your doctor if you are pregnant, planning a pregnancy, or breastfeeding. Product information in different regions may contain specific recommendations concerning contraception, pregnancy exposure, and breastfeeding.

The U.S. Medication Guide advises patients to discuss pregnancy and breastfeeding with their healthcare professional. The FDA prescribing information states that patients should be advised not to breastfeed.

You should not stop a necessary medicine abruptly or continue it during pregnancy without a personalised medical review.

Drug interactions

Tell your doctor and pharmacist about every medicine, supplement, and herbal product you use. Some medicines can increase or decrease tofacitinib levels in your body.

Important examples may include certain antifungal medicines, antibiotics, anticonvulsants, immunosuppressants, corticosteroids, biologic medicines, and herbal products such as St. John’s wort. The exact interaction depends on the medicine and your prescribed Xeljanz dose.

Do not combine Xeljanz with another JAK inhibitor, biologic DMARD, or potent immunosuppressant unless a specialist specifically directs you to do so. Combining immune-suppressing medicines can increase the risk of serious infection and other complications.

6. Xeljanz Compared With Other Drug Types

Xeljanz versus NSAIDs

NSAIDs such as ibuprofen and naproxen mainly reduce pain and inflammation by inhibiting cyclooxygenase enzymes. They can provide relatively quick symptom relief, but they do not function as DMARDs and do not directly modify the immune disease process in the same way as Xeljanz.

Xeljanz acts through the JAK-STAT signalling pathway and is prescribed for selected moderate-to-severe immune-mediated diseases. It is not an over-the-counter pain reliever and should not replace a doctor’s prescribed treatment plan.

NSAIDs can also interact with other medicines and may cause stomach, kidney, blood-pressure, or cardiovascular problems. Tell your clinician before using them with Xeljanz.

Xeljanz versus corticosteroids

Corticosteroids, such as prednisone, broadly suppress inflammation and immune activity. They can work quickly but may cause significant long-term problems, including high blood sugar, bone loss, weight gain, cataracts, and increased infection risk.

Xeljanz is a targeted synthetic DMARD rather than a steroid. Your specialist may use these medicines at different points in treatment, but you should not start, stop, or combine them without medical guidance.

Xeljanz versus biologic medicines

Biologic medicines are usually large protein-based therapies administered by injection or infusion. Many target one cytokine or immune-cell pathway outside the cell.

Xeljanz is a non-biologic oral DMARD. It is a small molecule that enters cells and inhibits JAK enzymes involved in the signalling of multiple cytokines.

Neither category is automatically safer or more effective for every person. Your doctor considers your diagnosis, previous treatment response, infection history, cardiovascular risk, cancer risk, pregnancy plans, kidney and liver function, and personal preferences.

Xeljanz versus other JAK inhibitors

Other JAK inhibitors include medicines such as baricitinib, upadacitinib, ruxolitinib, and fedratinib. Although they belong to the broader JAK-inhibitor family, they do not have identical indications, dosing schedules, selectivity, or safety information.

You should not assume that another JAK inhibitor is a direct substitute for Xeljanz. Each medicine has its own approved uses and prescribing restrictions.

The FDA has required boxed-warning information about serious heart-related events, cancer, blood clots, and death for certain JAK inhibitors used in chronic inflammatory conditions.

7. Frequently Asked Questions

Is Xeljanz a steroid?

No. Xeljanz is not a steroid. It is an oral JAK inhibitor and targeted synthetic DMARD containing tofacitinib.

Is Xeljanz a biologic?

No. Xeljanz is not a biologic medicine. It is a chemically synthesised small-molecule immunosuppressant taken by mouth.

Is Xeljanz an anti-inflammatory drug?

Yes, but it is more specific to classify Xeljanz as a JAK inhibitor and immunosuppressant. It reduces inflammation by interfering with immune-cell signalling rather than working like an NSAID such as ibuprofen.

Is Xeljanz a chemotherapy drug?

No. Xeljanz is not classified as chemotherapy. Doctors prescribe it for selected inflammatory and autoimmune conditions.

However, Xeljanz carries warnings about cancer and can affect immune function. You should discuss your personal cancer risk with your healthcare professional.

Is Xeljanz an immunosuppressant?

Yes. Xeljanz suppresses selected immune-system pathways. This can control autoimmune inflammation but may increase your susceptibility to serious infections.

What is the generic name for Xeljanz?

The generic name is tofacitinib. Xeljanz is the brand name, while Xeljanz XR refers to the extended-release formulation.

Can you take Xeljanz with methotrexate?

Some patients take Xeljanz with methotrexate, particularly for rheumatoid or psoriatic arthritis. Your doctor decides whether the combination is appropriate.

You should not combine Xeljanz with biologic DMARDs or potent immunosuppressants unless your specialist provides explicit instructions.

Does Xeljanz cure autoimmune disease?

Xeljanz does not cure autoimmune disease. It can reduce inflammation, control symptoms, and help maintain disease control in appropriately selected patients, but the underlying condition may remain chronic.

You should continue medical follow-up even when your symptoms improve.

How quickly does Xeljanz work?

The response varies according to your condition, disease severity, dose, previous treatments, and individual biology. Some people notice improvement earlier, while others need longer treatment before their clinician can judge the full response.

Do not increase the dose or stop treatment because you do not feel better immediately. Your prescriber will assess whether the medicine is working safely.

What should you remember about Xeljanz?

You can describe Xeljanz accurately as an oral Janus kinase inhibitor, tofacitinib, targeted synthetic DMARD, and immunosuppressant. It works inside immune cells by blocking JAK-mediated signalling that contributes to inflammation.

Because this mechanism also affects immune defence and other biological processes, Xeljanz requires prescription supervision, infection screening, laboratory monitoring, and careful assessment of cardiovascular, clotting, and cancer risks.

If your doctor has prescribed Xeljanz, take it exactly as directed and attend every recommended follow-up appointment. Contact your healthcare professional promptly if you develop signs of infection, a blood clot, heart attack, stroke, allergic reaction, or another serious problem.

The information above explains the medicine’s classification and general safety considerations; it does not replace your prescription label or personalised advice from a qualified healthcare professional.

Sources

• U.S. Food and Drug Administration, Xeljanz and Xeljanz XR Prescribing Information, revised October 2025. accessdata.fda
• European Medicines Agency, Xeljanz overview and product information. ema.europa
• U.S. Food and Drug Administration, JAK inhibitor safety communication. fda
• MedlinePlus, Tofacitinib Drug Information. medlineplus

Find more health insights from Medical Antidote.